Overall, our data show that preventing the loss of endogenous ADAMTS-4 activity by exogenous provision of an active human recombinant protein is detrimental for functional outcome in the context of ALS. The gene discussed is ADAMTS4; the disease is amyotrophic lateral sclerosis.